🏢 官网IRVEEVCodex · 实盘不做把握 5/10不做原因:证据不足
北京时间·🕒 发布 19:03:00·⟳ 抓取 08-26 22:34:23·⚡ 决策 08-25 19:16:54 −1d03h·63.2 天前
Veeva宣布Biogen全球采用Vault CRM，验证客户迁移但未披露金额
事件对Veeva方向偏利好，但缺少合同金额和指引增量，且同类Vault CRM客户迁移已是既有叙事，无法形成足够清晰的短线正期望。
📄 原文VEEV↗ 原文
Veeva Vault CRM Selected by Biogen
Unified commercial platform to help speed the delivery of medicines to patients PLEASANTON, Calif. , Aug. 25, 2026 /PRN…
不做 Veeva Systems（VEEV.US）
Biogen采用Vault CRM方向利好，但无合同金额、无ARR/RPO或指引增量，且同类客户迁移公告近期已出现，盘前不追买。
不做 Biogen（BIIB.US）
Biogen是客户方，CRM迁移对其短线收入利润影响不直接，不构成交易催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Veeva一手公告确认Biogen全球采用Vault CRM，说明其生命科学CRM迁移战略继续获得大型药企客户验证；但本次没有披露ACV、订阅期限、上线节奏或指引变化，无法估算新增收入占Veeva收入或市值的比例。Biogen作为客户方财务弹性更弱，因此本次不追买VEEV.US，也不交易BIIB.US。
消息传播链
- Veeva官方披露Biogen全球承诺采用Vault CRM，未披露合同金额或业绩指引。
- PRNewswire同步发布同一通稿，未增加金额、合同期限或收入确认信息。
关键理由
- Biogen全球承诺迁移Vault CRM验证Veeva在生命科学CRM替代周期中的客户获取能力。
- 公告未披露ACV、ARR、RPO、上线节奏或指引上调，无法估算本事件对Veeva收入、利润或市值的增量占比。
- 客户采用是正面商业验证，但更像既有Vault CRM迁移叙事延续，而不是足以单独重估的合同披露。
主要风险
- 若后续财报或管理层披露Biogen合同规模显著高于预期，本次AVOID可能错过后续上修。
- Veeva临近季度业绩窗口，短线价格更可能由财报、指引和RPO变化主导。
反向证据
- 做多前查反向 · 来源 filing · 日期 2026-08-25 · 影响 weakens
本次Veeva官方通稿未披露合同金额、订阅期限、上线节奏或收入指引上调。
检索:Veeva Vault CRM Biogen contract value revenue guidance 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-11 · 影响 weakens
Veeva近期已宣布Lilly全球采用Vault CRM，本次Biogen公告更像客户迁移叙事延续。
检索:Veeva Vault CRM large pharma selected prior customer announcements 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例使本次结论偏向不追买，除非后续财报或管理层披露Biogen带来明确ACV、RPO或指引增量。
方向:同类公告方向偏正面，但更多证明客户采用趋势，未证明无金额公告具备稳定短线超额收益。
涨幅量级:缺少高相似且锚点干净的event_study测算，不能用先例给出可靠tp/sl幅度。
形态:可确认同类客户采用公告并非稀缺事件，边际新鲜度可能递减；未能证明持续见光死或稳定上涨。
历史先例(按相似度)
- 相似度 7/10 VEEV 2026-08-11 Veeva宣布Eli Lilly全球采用Vault CRM。 原文 ↗
事件后 +1日 +0.8% · +2日 +2.9% · +3日 +7.7% · +4日 +3.9% · +5日 +1.6%
⚠锚前1-2日已异动7.8%>锚定日0.8%·未核对目标相位 — 该行涨幅别用来定止盈止损
相似度依据:同为Veeva宣布大型药企全球采用Vault CRM，但同样缺少合同金额披露。
经验:大型客户采用能强化SaaS迁移叙事，但无金额和指引变化时较难单独支撑短线追买。 - 相似度 6/10 VEEV 2023-11-27 Veeva宣布顶级生物制药公司承诺采用Vault CRM。 原文 ↗
事件后 +1日 -1.8% · +2日 -1.0% · +3日 -1.8% · +4日 -1.3% · +5日 +1.3%
⚠未核对目标相位 — 该行涨幅别用来定止盈止损
相似度依据:同为顶级药企迁移Vault CRM，但处于更早产品采用阶段，可比性弱于近期重复客户公告。
经验:早期标杆客户更有叙事价值，后续重复客户公告边际冲击可能递减。
原文全文
展开原文 · 2,709 字
Unified commercial platform to help speed the delivery of medicines to patients
PLEASANTON, Calif.
,
Aug. 25, 2026
/PRNewswire/ --
Veeva Systems
(NYSE: VEEV) today announced that Biogen has committed to
Veeva Vault CRM
globally.
"We are honored to provide Vault CRM as the agentic commercial foundation for Biogen as it delivers medicines that transform patients' lives," said Tom Schwenger, president and CCO at Veeva. "Bringing complex treatments to market requires a highly adaptive commercial strategy, and we are committed to providing the advanced capabilities needed to help accelerate patient impact around the world."
"Biogen and Veeva share a deep commitment to customer experience and innovation," said Guy Hadari, senior vice president, global CIO at Biogen. "We are excited to expand our strategic partnership with Veeva by moving to Vault CRM."
Vault CRM is part of the
Vault CRM Suite
which includes the
Agentic Call Report
to generate Commercial Evidence. These applications provide the technology foundation for agentic commercial, the new commercial model that leverages AI to get the right medicines to more patients.
About Veeva Systems
Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a
Public Benefit Corporation
, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit
veeva.com
.
Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended April 30, 2026, which you can find
here
(a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at
sec.gov
.
Contact:
Maria Scurry
Veeva Systems
maria.scurry@veeva.com
Meera Lakhani-Patel
Veeva Systems, Europe
meera.lakhani-patel@veeva.com
View original content to download multimedia:
https://www.prnewswire.com/news-releases/veeva-vault-crm-selected-by-biogen-302858894.html
SOURCE Veeva Systems
PLEASANTON, Calif.
,
Aug. 25, 2026
/PRNewswire/ --
Veeva Systems
(NYSE: VEEV) today announced that Biogen has committed to
Veeva Vault CRM
globally.
"We are honored to provide Vault CRM as the agentic commercial foundation for Biogen as it delivers medicines that transform patients' lives," said Tom Schwenger, president and CCO at Veeva. "Bringing complex treatments to market requires a highly adaptive commercial strategy, and we are committed to providing the advanced capabilities needed to help accelerate patient impact around the world."
"Biogen and Veeva share a deep commitment to customer experience and innovation," said Guy Hadari, senior vice president, global CIO at Biogen. "We are excited to expand our strategic partnership with Veeva by moving to Vault CRM."
Vault CRM is part of the
Vault CRM Suite
which includes the
Agentic Call Report
to generate Commercial Evidence. These applications provide the technology foundation for agentic commercial, the new commercial model that leverages AI to get the right medicines to more patients.
About Veeva Systems
Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a
Public Benefit Corporation
, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit
veeva.com
.
Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended April 30, 2026, which you can find
here
(a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at
sec.gov
.
Contact:
Maria Scurry
Veeva Systems
maria.scurry@veeva.com
Meera Lakhani-Patel
Veeva Systems, Europe
meera.lakhani-patel@veeva.com
View original content to download multimedia:
https://www.prnewswire.com/news-releases/veeva-vault-crm-selected-by-biogen-302858894.html
SOURCE Veeva Systems
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。